Clinical Laserthermia Systems AB (publ) (STO:CLS.B)
Sweden · Delayed Price · Currency is SEK 3.370
-0.110 (-3.16%)
Jun 15, 2026, 11:00 AM CET
STO:CLS.B Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 14.27 | 17.49 | 18.78 | 8.27 | 6.27 | 2.25 |
Other Revenue | - | - | -0 | 0 | - | - |
| 14.27 | 17.49 | 18.78 | 8.27 | 6.27 | 2.25 | |
Revenue Growth (YoY) | -29.16% | -6.90% | 127.03% | 31.99% | 179.20% | 68.54% |
Cost of Revenue | 5.46 | 6.57 | 8.36 | 5.28 | 9.06 | 5.88 |
Gross Profit | 8.81 | 10.92 | 10.42 | 3 | -2.79 | -3.63 |
Selling, General & Admin | 36.79 | 37.33 | 62.04 | 66.13 | 62.29 | 54.2 |
Other Operating Expenses | 0.26 | 0.19 | -0.06 | -0.36 | -0.09 | -0 |
Operating Expenses | 39.64 | 40.11 | 64.65 | 68.48 | 64.65 | 56.98 |
Operating Income | -30.84 | -29.19 | -54.23 | -65.48 | -67.44 | -60.61 |
Interest Expense | -0.04 | -0.09 | -0.43 | -9.76 | -10.97 | -6.41 |
Interest & Investment Income | 2.21 | - | 6.83 | 0.3 | 7.4 | 2.91 |
Currency Exchange Gain (Loss) | - | - | -0.02 | -0.45 | -0 | -0.07 |
Other Non Operating Income (Expenses) | 0.18 | 0.24 | -0 | -0 | -0.22 | 0.03 |
EBT Excluding Unusual Items | -28.48 | -29.04 | -47.86 | -75.39 | -71.24 | -64.14 |
Gain (Loss) on Sale of Investments | -5.7 | -13 | - | -5.48 | -0.03 | - |
Pretax Income | -34.18 | -42.05 | -47.86 | -80.88 | -71.27 | -64.14 |
Earnings From Continuing Operations | -34.18 | -42.05 | -47.86 | -80.88 | -71.27 | -64.14 |
Minority Interest in Earnings | 0.43 | 0.43 | 0.24 | 1.08 | 0.61 | 0.53 |
Net Income | -33.75 | -41.61 | -47.62 | -79.79 | -70.66 | -63.62 |
Net Income to Common | -33.75 | -41.61 | -47.62 | -79.79 | -70.66 | -63.62 |
Shares Outstanding (Basic) | 28 | 26 | 11 | 3 | 0 | 0 |
Shares Outstanding (Diluted) | 28 | 26 | 11 | 3 | 0 | 0 |
Shares Change (YoY) | 92.75% | 134.96% | 227.83% | 705.35% | 45.02% | 30.24% |
EPS (Basic) | -1.19 | -1.61 | -4.32 | -23.76 | -169.43 | -221.20 |
EPS (Diluted) | -1.19 | -1.61 | -4.32 | -23.76 | -169.43 | -221.20 |
Free Cash Flow | -34.79 | -35.91 | -63.93 | -68.6 | -82.1 | -66.32 |
Free Cash Flow Per Share | -1.23 | -1.39 | -5.81 | -20.42 | -196.85 | -230.61 |
Gross Margin | 61.72% | 62.44% | 55.47% | 36.23% | -44.51% | -161.69% |
Operating Margin | -216.13% | -166.90% | -288.72% | -791.47% | -1075.95% | -2699.97% |
Profit Margin | -236.57% | -237.96% | -253.54% | -964.46% | -1127.31% | -2833.63% |
Free Cash Flow Margin | -243.83% | -205.33% | -340.34% | -829.16% | -1309.76% | -2954.16% |
EBITDA | -28.24 | -26.6 | -53.93 | -65.14 | -67.05 | -59.93 |
EBITDA Margin | -197.97% | -152.12% | -287.10% | - | - | - |
D&A For EBITDA | 2.59 | 2.58 | 0.3 | 0.34 | 0.39 | 0.68 |
EBIT | -30.84 | -29.19 | -54.23 | -65.48 | -67.44 | -60.61 |
EBIT Margin | -216.13% | -166.90% | -288.72% | - | - | - |
Revenue as Reported | - | - | - | - | - | 2.41 |